
Reproduction cells (germ cells) in your ovaries give birth to ovarian germ cell cancers. The ovaries and two small pelvic glands are essential for the female reproductive tract. During fertile times, they produce eggs. Someday, the germ cells in your ovaries mature and turn into eggs, or "germ"-inate. When an ovarian germ cell tumor happens, some cells mass together to form a misshapen lump.
Ovarian germ cell tumors often develop in only one ovary but occasionally occur in both.
Most ovarian germ cell tumors are benign (not cancerous) and rarely become malignant (cancerous). Malignant germ cell tumors, which have the potential to spread and harm normal tissue, are an uncommon type of ovarian cancer.
These are the most common types of ovarian germ cell tumors:
Mature teratoma (Dermoid Cyst): The most common type of ovarian germ cell tumors are mature teratomas, or dermoid cysts, which are benign tumors. Most diagnosed individuals are in their teens, twenties, or thirties.
Dysgerminoma: The most common type of cancerous ovarian germ cell tumor is referred to as a dysgerminoma. Most tumors (70 percent of the diagnosis) are not believed to be aggressive (rapid-spreading) and respond well to treatment. Most individuals with diagnoses fall in their 20s or 30s.
Immature teratoma: A fast-growing malignant tumor, an immature teratoma can metastasise—spread from your ovary to other areas of your body. It is more common in people under the age of twenty.
Endodermal sinus tumors or yolk sac tumors are cancers that metastasise rapidly. They are most common in those below the age of twenty. Children who have not yet commenced their periods are affected in up to 40% of the diagnoses.
Mixed germ cell tumors: Malignant tumors referred to as mixed germ cell tumors usually include a mixture of yolk sac and dysgerminoma tumors.
Early treatment is crucial to enhance survival and preserve fertility in germ cell ovarian malignancy. Early treatment, including surgery and chemotherapy, offers a greater chance of eradicating the tumor and halting its spread. Delayed treatment can lead to metastases, issues, and reduced conceptions. Early treatment is most beneficial for remission, organ function, and quality of life.
The early detection of ovarian germ cell cancers may be challenging. Unless they are extensive, benign tumors might not show symptoms, while symptoms of malignant tumors cannot appear until the malignancy has progressed.
Some symptoms to look out out for are:
Causes
Sex cells, or germ cells, may change (mutate) and grow into ovarian germ cell tumors. Researchers continue to study the reasons behind these tumors and the chances of getting them.
Ovarian germ cell tumors may affect anyone with ovaries, yet they are much more prevalent in those who are younger and in their reproductive years
Risk Factors
The following are germ cell ovarian cancer risk factors:
In India, recent research has focused on improving the detection and treatment of ovarian germ cell tumors (OGCTs). The application of neoadjuvant chemotherapy to reduce tumors before surgery and better management methods to preserve fertility and minimise treatment impact are some of the improvements.
The increasing use of multidisciplinary approaches facilitates individualised care. Research also emphasises the significance of early detection and the integration of personalised treatment regimens for young women with such malignancies, which enhance patient outcomes and boost survival rates.
There is no method for preventing germ cell cancer. However, regular check-ups can enable your physician to monitor your health and assess your cancer risk.
Surgery: Your doctor might suggest having an oophorectomy to have either one or both of your ovaries or your fallopian tubes removed. If cancer extends beyond your fallopian tubes and ovaries, you would have a total hysterectomy done to have your cervix and uterus removed.
Chemotherapy: When you have chemotherapy, your doctor administers medicine into your veins, typically through an infusion. Chemotherapy medications destroy cancerous cells and prevent them from growing. You'll get chemo treatments for many weeks or even months.
Cost Start From USD 600 - USD 700Explore Options
MediRehab (chain of Rehab centres - Part of MediGence) provides comprehensive rehabilitation services designed to support Germ Cell Ovarian Cancer patients in India. These services include:









Pune, India
Ruby Hall Clinic located in Pune, India is accredited by NABH. Also listed below are some of the most prominent infrastructural details:

Hyderabad, India
Yashoda Hospital, Malakpet located in Hyderabad, India is accredited by NABH, NABL. Also listed below are some of the most prominent infrastructural details:

Ghaziabad, India
Opinion & Option
We submit the most accurate opinion and options from one or more countries for your review
Consult Privately
Consult with a certified specialist privately on our telemedicine platform even before you decide to travel
Logistics
We handle flights, visas, transfers, and accommodation—so you can focus on your health.
Recovery
Our In-house rehabilitation service packages to better your recovery and treatment outcome
India is a leading destination for treating germ cell ovarian cancer due to its excellent medical facilities, experienced physicians, and affordable healthcare. The country offers advanced medical treatments, such as radiation, chemotherapy, and surgery, supported by clinical research and cutting-edge technology. India provides world-class care without compromising outcomes, and treatment costs are lower than in Western countries. It is also an affordable and convenient cancer treatment option since foreign patients get specialist services such as post-treatment care and flight assistance.
To determine whether a tumor is malignant or not, medical experts apply a process called staging to classify the malignancy. They use imaging methods like positron emission tomography (PET) and CT scans to assess the size and pinpoint the tumour. For the most part, cancer is easier to treat when it is in an earlier stage.
The following are the stages of malignant ovarian germ cell tumors:
Stage 1: The malignancy is confined to your ovaries alone.
Stage 2: Your fallopian tubes or uterus are part of the other pelvic tissues where cancer has spread.
Stage 3: While the cancer has not yet spread beyond your abdomen, it has invaded your lymph nodes and the peritoneum, the lining of your pelvic organs and abdominal cavity.
Stage 4 (metastatic cancer): The cancer has spread to organs and tissues beyond your abdomen, for example, your lungs, or it has grown into your liver or spleen.
No, germ cell ovarian cancer is not very common. Only 2% to 5% of all ovarian cancers are due to it. This type of cancer occurs more in women younger than 30 and predominantly in young women, often in their reproductive years. Although less prevalent than other forms of ovarian cancer, its potential impact on fertility and overall health makes it a cause for concern.
Women under 30 are more likely to get germ cell ovarian cancer, particularly if they have a family history of other ovarian cancers or have inherited syndromes like BRCA1 or BRCA2. Other risk factors are infertility, some ethnic groups, endometriosis, PCOS, and having a past germ cell cancer. It is still a very unusual type of cancer, however, and most women with these risk factors may not develop it.
Germ cell ovarian cancer cannot be entirely prevented at this point. However, a healthy lifestyle, managing risk factors, and regular checkups with the physician can facilitate early detection and a successful outcome from treatment. No specific preventive interventions for germ cell ovarian cancer are available at this time; however, genetic counseling and testing can help estimate risk and guide preventive measures for those with a family history or genetic predisposition.
Overall, germ cell ovarian cancer has a relatively high survival rate, especially if it is detected and treated early. Approximately 87-90% of women with early-stage germ cell ovarian cancer live for five years. Approximately 80–85% of women live for five years or more, which is still a relatively good survival rate even for those with advanced disease. The prognosis is influenced by factors such as the age of the patient, response to treatment, and stage at diagnosis.
Menstruation and hormone levels can be impacted by germ cell ovarian cancer, mainly when surgery, chemotherapy, or radiation therapy is employed as a treatment. The function of hormones such as estrogen and progesterone can be interrupted by surgery that removes one or both ovaries, and may lead to abnormal periods or premature menopause.
Chemotherapy and radiation damage the eggs and the ovarian tissue and thus impair ovarian function. This may cause hormonal imbalance, menstrual cycle abnormality, and temporary or long-term infertility. However, if only one ovary is affected or if the treatments do not significantly damage the ovaries, a few women may still have menstrual periods regularly.
Genetic testing might be beneficial to patients with germ cell ovarian cancer, especially if the patient was diagnosed at a young age or if there is a family history of the illness. Testing can identify inherited mutations in the BRCA1 or BRCA2 genes, which are more commonly associated with other types of ovarian cancer but are still applicable.
Genetic testing can also help determine treatment possibilities and assess family members' risk. However, routine genetic testing for germ cell ovarian cancer is not typically performed in the absence of specific risk factors or signs.
The severity of the cancer and the treatment plan generally decide the duration of germ cell ovarian cancer treatment. Treatment for cancer at an early stage can involve surgery followed by a few cycles of chemotherapy, which generally take three to six months.
In the later stages, a combination of surgery, chemotherapy, and possibly radiation is administered, leading to a longer treatment regimen extending from six months to twelve months or more. Regular follow-ups for monitoring and continuing therapies can then be required beyond the initial treatment time.